Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
D006585:Altretamine / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003606:Dacarbazine / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D006144:Guanazole / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011929:Razoxane / Q000627:therapeutic use; D014481:United States
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D009607:Nitrosourea Compounds; D001761:Bleomycin; D011929:Razoxane; D003606:Dacarbazine; D004317:Doxorubicin; D001215:Asparaginase; D006144:Guanazole; D001374:Azacitidine; D002945:Cisplatin; D006585:Altretamine; D007069:Ifosfamide